An Association Between Inflammatory State and Left Ventricular Hypertrophy in Hemodialysis Patients

References

• Foley, R N.; Parfrey, P S.; Sarnak, M J. Epidemiology of cardiovascular disease in chronic renal disease. J. Am. Soc. Nephrol. 1998, 9 (12 Suppl.), S16–S23. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Brown, J H.; Hunt, L P.; Vites, N P.; Short, C D.; Gokal, R.; Mallick, N P. Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol. Dial. Transplant. 1994, 9 (8), 1136–1142. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Silberberg, J S.; Barre, P E.; Prichard, S S.; Sniderman, A D. Impact of left ventricular hypertrophy on survival in end stage renal disease. Kidney Int. 1989, 36, 286–290. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Nakamura, S.; Sasaki, O.; Nakahama, H.; Inenaga, T.; Kimura, G. Left ventricular hypertrophy is a risk factor independent of hypertension in survival of hemodialyzed patients. Ren. Fail. 2002, 24 (2), 175–186. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Foley, R N.; Parfrey, P S.; Harnett, J D.; Kent, G M.; Murray, D C.; Barre, P E. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J. Am. Soc. Nephrol. 1995, 5, 2024–2031. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Amann, K.; Rychlik, I.; Miltenberger-Milteny, G.; Ritz, E. Left ventricular hypertrophy in renal failure. Kidney Int. 1998, 54 (Suppl. 68), S78–S85. [CSA], [CROSSREF]
   Google Scholar
• London, G M. Left ventricular hypertrophy: why does it happen? Nephrol. Dial. Transplant. 2003, 18 (Suppl. 8), viii2–viii6., [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• London, G M.; Pannier, B.; Guerin, A P.; Parfrey, P S. Cardiac disease in chronic uremia: Pathogenesis. Adv. Renal Replace. Ther. 1997, 4, 194–211. [CSA]
   PubMedGoogle Scholar
• Stompor, T.; Pasowicz, M.; Sullowicz, W.; Dembinska- Kiec, A.; Janda, K.; Wojcik, K.; Tracz, W.; Zdzienicka, A.; Klimeczek, P.; Janusz-Grzybowska, E. An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. Am. J. Kidney Dis. 2003, 41 (1), 203–211. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Santoro, A.; Manchini, E. Cardiac effects of chronic inflammation in dialysis patients. Nephrol. Dial. Transplant. 2002, 17 (Suppl. 8), 10–15. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Wanner, C.; Zimmermann, J.; Shwedler, S.; Metzger, T. Inflammation and cardiovascular risk in dialysis patients. Kidney Int. 2002, 61 (Suppl. 80), S.99–S.102. [CSA]
   Google Scholar
• Kaysen, G A. The microinflammatory state in uremia; Causes and potential consequences. J. Am. Soc. Nephrol. 2001, 12, 1549–1557. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Caglar, K.; Peng, Y.; Pupim, L B.; Flakoll, P J.; Levenhagen, D.; Hakim, R M.; Ikizler, T A. Inflammatory signals associated with hemodialysis. Kidney Int. 2002, 62 (4), 1408–1416. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Stenvinkel, P.; Barany, P.; Heimburger, O.; Pechoits-Filho, R.; Lindholm, B. Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Int. Suppl. 2002, 80, 103–108. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Yudkin, J S.; Kumari, M.; Humphries, S E.; Mohamed-Ali, V. Inflammation, obesity, stres and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000, 148 (2), 209–214. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Descamps-Latscha, B.; Herbelin, A.; Nguyen, A T.; Roux-Lombard, P.; Zingraff, J.; Moynot, A.; Verger, C.; Dahmane, D.; de Groote, D.; Jungers, P. Balance between IL-1β, TNF-α and their specific inhibitors in chronic renal failure and maintenance dialysis. J. Immunol. 1995, 154 (2), 882–892. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Erren, M.; Reinecke, H.; Junker, R.; Fobker, M.; Schulte, H.; Schurek, J O.; Kropf, J.; Kerber, S.; Breithardt, G.; Assmann, G.; Cullen, P. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler. Thromb. Vasc. Biol. 1999, 19 (10), 2355–2363. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Hirote, H.; Yoshida, K.; Kishimoto, T.; Taga, T. Continuous activation of gp 130, a signal-transducing receptor component for interleukin-6 related cytokines, causes myocardial hypertrophy in mice. Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 4862–4866. [CSA]
   PubMedGoogle Scholar
• Bryant, D.; Becker, L.; Richardson, J.; Shelton, J.; Franco, F.; Peshock, R.; Thompson, M.; Giroir, B. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor alpha. Circulation 1998, 97 (14), 1375–1381. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bozkurt, B.; Kribbs, S.; Clubb, M., Jr.; Michael, L H.; Didenko, V V.; Hornsby, P J.; Seta, Y.; Oral, H.; Spinale, F G.; Mann, D L. Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998, 97, 1382–1391. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Yokoyama, T.; Nakano, M.; Bednarzczyk, J L.; McIntyre, B W.; Entman, M.; Mann, D L. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 1997, 95 (5), 1247–1252. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Espinoza, M.; Aguilera, A.; Auxiliadora, B M.; Codoceo, R.; Caravaca, E.; Cirugeda, A.; del Peso, G.; Hevia, C.; Selgas. Tumor necrosis factor alpha as a uremic toxin: correlation with neuropathy, left ventricular hypertrophy, anemia and hypertriglyceridemia in peritoneal dialysis patients. Adv. Perit. Dial. 1999, 15, 82–86. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Sahn, D J.; DeMaria, A.; Kisslo, J.; Weyman, A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978, 58, 1072–1083. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Devereux, R B.; Alonso, D R.; Lutas, E M.; Gottlieb, G J.; Campo, E.; Sachs, I.; Reichek, N. Echocardiographic assesment of left ventricular hypertrophy: Comparison to necropsy findings. Am. J. Cardiol. 1986, 57, 450–458. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Savage, D D.; Garrison, R J.; Kannel, W B Levy, D.; Anderson, S J.; Stokes, J., III; Feinleib, M.; Castelli, W P. The spectrum of left ventricular hypertrophy in a general population sample: the Framingham Study. Circulation 1987, 75 (1 Pt. 2), I26–I33. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Levin, A.; Singer, J.; Thompson, C R.; Ross, H.; Lewis, M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am. J. Kidney Dis. 1996, 27 (3), 347–354. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Parfrey, P S.; Foley, R N.; Harnett, J D.; Kent, G.M.; Martin, C J.; Murray, D C.; Barre, P E. Clinical and echocardiographic disease in patients starting end-stage renal disease. Kidney Int. 1995, 47, 186–192. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• McMahon, L P.; Roger, S D.; Levin, A. Slimheart Investigators Group. Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease. J. Am. Soc. Nephrol. 2004, 15 (6), 1640–1647. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Harnett, J D.; Kent, G M.; Barre, P E.; Taylor, R.; Parfrey, P S. Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J. Am. Soc. Nephrol. 1994, 4, 1486–1490. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Covic, A.; Goldsmith, D J.A.; Georgescu, G.; Venning, M C.; Ackrill, P. Echocardiographic findings in long term, long hour hemodialysis patients. Clin. Nephrol. 1996, 45 (2), 104–110. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Moon, K H.; Song, I S.; Yang, W S.; Shin, Y T.; Kim, S B.; Song, J K.; Park, J S. Hypoalbuminemia as a risk factor for progressive left-ventricular hypertrophy in hemodialysis patients. Am. J. Nephrol. 2000, 20, 396–401. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bech-Hanssen, O.; Wallentin, I.; Larsson, O.; Nyberg, G. Reduced left ventricular hypertrophy in type 1 diabetic patients with end-stage renal failure. A comparison between groups investigated 1977-80 and 1991-93. Nephrol. Dial. Transplant. 1996, 11 (8), 1547–1552. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Low-Friedrich, I.; Grutzmacher, P.; Marz, W.; Bergmann, M.; Schoeppe, W. Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients. Am. J. Nephrol. 1991, 11 (1), 54–60. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Silberberg, J.; Racine, N.; Barre, P.; Sniderman, A D. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can. J. Cardiol. 1990, 6 (1), 1–4. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Park, C W.; Oh, Y S.; Shin, Y S.; Kim, C M.; Kim, Y S.; Kim, S Y.; Choi, E J.; Chang, Y S.; Bang, B K. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am. J. Kidney Dis. 1999, 33 (1), 73–81. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Cannella, G.; Paoletti, E.; Delfino, R.; Cannella, G.; Paoletti, E.; Delfino, R.; Peloso, G.; Molinari, S.; Traverso, G B. Regression of left ventricular hypertrophy in hemodialysed uremic patients on long-term antihypertensive therapy. Kidney Int. 1993, 44, 881–886. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ozkahya, M.; Ok, E.; Cirit, M.; Ozkahya, M.; Ok, E.; Cirit, M.; Aydin, S.; Akcicek, F.; Basci, A.; Dorhout Mees, E J. Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs. Nephrol. Dial. Transplant. 1998, 13 (6), 1489–1493. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• de Lima, J J.; Abensur, H.; Krieger, E M.; Pileggi, F. Arterial blood pressure and left ventricular hypertrophy in haemodialysis patients. J. Hypertens. 1996, 14 (8), 1019–1024. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Ganau, A.; Devereux, R B.; Pickering, T G.; , et al. Relation of left ventricular hemodynamic load and contractile performance to left ventricular mass in hypertension. Circulation 1990, 81 (1), 25–36. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Tucker, B.; Fabbian, F.; Giles, M.; Thuraisingham, R C.; Raine, A E.G.; Baker, L R.I. Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. Nephrol. Dial. Transplant. 1997, 12, 724–728. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Nishikimi, T.; Minami, J.; Tamano, K.; Nishikimi, T.; Minami, J.; Tamano, K.; Takahashi, M.; Numabe, A.; Futoo, Y.; Honda, T.; Kobayashi, T.; Uetake, S.; Mori, Y.; Saito, T.; Matsuoka, H. Left ventricular mass relates to average systolic blood pressure, but not loss of circadian blood pressure in stable hemodialysis patients: an ambulatory 48-hour blood pressure study. Hypertens. Res. 2001, 24 (5), 507–514. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Lin, Y P.; Chen, C H.; Yu, W C.; Hsu, T L.; Ding, P Y.; Wang, W C. Left ventricular mass and hemodynamic overload in normotensive hemodialysis patients. Kidney Int. 2002, 62, 1828–1838. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Rambausek, M.; Ritz, E.; Mall, G.; Mehls, O.; Katus, H. Myocardial hypertrophy in rats with renal insufficiency. Kidney Int. 1985, 28, 775–782. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Singh, N P.; Banal, R.; Thakur, A.; Kohli, R.; Bansal, R C.; Agarval, S K. Effect of membrane composition on cytokine production and clinical symptoms during hemodialysis: a crossover study. Ren. Fail. 2003, 25 (3), 411–430. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Sitter, T.; Bergner, A.; Schiffl, H. Dialysate related cytokine induction and response to recombinant erythropoietin in haemodialysis patients. Nephrol. Dial. Transplant. 2000, 15 (8), 1207–1211. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Niebauer, J.; Volk, H D.; Kemp, M.; Dominguez, M.; Schumann, R R.; Rauchhaus, M.; Poole-Wilson, P A.; Coats, A J.; Anker, S D. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999, 353 (9167), 1838–1842. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kato, A.; Odamaki, M.; Takita, T.; Maruyama, Y.; Kumagai, H.; Hishida, A. Association between interleukin-6 and carotid atheroslerosis in hemodialysis patients. Kidney Int. 2002, 61 (3), 1143–1152. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Park, C W.; Shin, Y S.; Kim, C M.; Lee, S Y.; Yu, S E.; Kim, S.Y.; Choi, E J.; Chang, Y S.; Bang, B K. Increased C-reactive protein following hemodialysis predicts cardiac hypertrophy in chronic hemodialysis patients. Am. J. Kidney Dis. 2002, 40 (6), 1230–1239. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Losito, A.; Kalidas, K.; Santoni, S.; Jeffery, S. Association of interleukin-6 − 174 − G/C promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients. Kidney Int. 2003, 64, 616–622. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Humphries, S E.; Luong, L A.; Ogg, M S.; Hawe, E.; Miller, G J. The interleukin-6 174 G/C polymorphism associated with risk of coronary artery disease and systolic blood pressure in healthy men. Eur. Heart J. 2001, 22, 2219–2220. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Jeron, A.; Straub, R H.; Kaiser, T.; Riegger, G A.; Muders, F. Systemic immunosuppression fails to suppress cardiac cytokine induction in pressure overload hypertrophy in rats. Immunobiology 2002, 205 (1), 51–60. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Nakamura, K.; Mihara, K. Inhibitory effects of neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 1998, 98, 794–799. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Liu, J Y.; Brass, D M.; Hoyle, G W.; Brody, A R. TNF alpha receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestosis fibers. Am. J. Pathol. 1998, 153, 1839–1847. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Nagueh, S F.; Stetson, S J.; Lakkis, N M.; Killip, D.; Perez-Verdia, A.; Entman, M L.; Spencer, W H., III; Torre-Amione, G. Decreased expression of tumor necrosis factor-alpha and regression of hypertrophy after nonsurgical septal reduction therapy for patients with hypertrophic obstructive cardiomyopathy. Circulation 2001, 103 (14), 1844–1850. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Moustapha, A.; Naso, A.; Nahlawi, M.; Gupta, A.; Arheart, K L.; Jacobsen, D W.; Robinson, K.; Dennis, V W. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998, 97 (2), 138–141. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Manns, B J.; Burgess, E D.; Hyndman, M E.; Parsons, H G.; Schaefer, J P.; Scott-Douglas, N W. Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. Am. J. Kidney Dis. 1999, 34 (4), 669–677. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Blacher, J.; Demuth, K.; Guerin, A P.;Blacher, J.; Demuth, K.; Guerin, A P.; Vadez, C.; Moatti, N.; Safar, M E.; London, G M. Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease. J. Nephrol. 1999, 22, 248–255. [CSA], [CROSSREF]
   Google Scholar
• Franke, S.; Muller, A.; Sommer, M.; Busch, M.; Kientsch-Engel, R.; Stein, G. Serum levels of total homocysteine, homocysteine metabolites and glycation end products in patients after renal transplantation. Clin. Nephrol. 2003, 59 (2), 88–97. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar